Genetic testing using an arrhythmia and cardiomyopathy genes panel should be considered in every infant or child with cardiac conduction system disease and whose mothers are anti-Ro/SSA negative, with cascade testing whether they are positive. This evidence concerns the gene CALR and Arrhythmia.